comparemela.com

Latest Breaking News On - Mc2 therapeutics - Page 1 : comparemela.com

MC2 Therapeutics Announces Positive Phase 2a Results of

MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in.

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

La investigación clínica de MC2 Therapeutics se presentará en cuatro pósters en EADV 2021

-La investigación clínica de MC2 Therapeutics se presentará en cuatro pósters en el congreso de la European Academy of Dermatology and Venereology - EADV 2021.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.